SIPONIMOD
Information current as at: 1 June 2026
The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.
PBAC meeting date: March 2020
Submission Details
- Brand name:
-
- Mayzent®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Multiple sclerosis (MS)
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- New listing (Minor)
- Comment:
- Submission withdrawn
- Submission sponsor:
- Novartis Pharmaceuticals Australia Pty Ltd
- Other PBAC consideration:
Progress Details
-
Submission received for: - March 2020 PBAC meeting
-
Opportunity for consumer comment: - Open 24/12/2019 and close 12/02/2020 (see PBS Website)
-
PBAC meeting: - Not applicable
-
PBAC outcome published: - Not Applicable (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
PBAC Outcome
Case ID: a149
Page last updated: 31 March 2026